Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Other Operating Expenses (2016 - 2026)

Aytu Biopharma has reported Other Operating Expenses over the past 15 years, most recently at $6.5 million for Q4 2025.

  • Quarterly Other Operating Expenses rose 5.34% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.4 million through Dec 2025, up 27.5% year-over-year, with the annual reading at $32.9 million for FY2025, 27.5% up from the prior year.
  • Other Operating Expenses was $6.5 million for Q4 2025 at Aytu Biopharma, up from $5.8 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $14.4 million in Q4 2022 and troughed at -$53.1 million in Q1 2022.
  • The 5-year median for Other Operating Expenses is $6.3 million (2024), against an average of -$383736.8.
  • Year-over-year, Other Operating Expenses tumbled 422.75% in 2021 and then surged 224.98% in 2022.
  • A 5-year view of Other Operating Expenses shows it stood at -$11.5 million in 2021, then surged by 224.98% to $14.4 million in 2022, then crashed by 57.49% to $6.1 million in 2023, then rose by 0.93% to $6.2 million in 2024, then increased by 5.34% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Operating Expenses are $6.5 million (Q4 2025), $5.8 million (Q3 2025), and $14.0 million (Q2 2025).